Valuation: Nykode Therapeutics

Market Cap 909M 94.04M 82.22M 75.84M 69.72M 132M 9.05B 134M 905M 355M 4.42B 353M 345M 15.24B P/E 2026 *
-4.31x
P/E 2027 * -30.1x
Enterprise Value 424M 43.88M 38.36M 35.39M 32.53M 61.64M 4.22B 62.69M 422M 166M 2.06B 165M 161M 7.11B EV / Sales 2026 *
-
EV / Sales 2027 * 2.05x
Free-Float
56.4%
Yield 2026 *
-
Yield 2027 * -
1 week-8.39%
Current month-13.51%
1 month-11.59%
3 months-11.87%
6 months+10.08%
Current year+15.46%
1 week 2.72
Extreme 2.72
3.03
1 month 2.72
Extreme 2.72
3.3
Current year 2.21
Extreme 2.21
4.1
1 year 1.44
Extreme 1.44
4.1
3 years 1.44
Extreme 1.44
30.18
5 years 1.44
Extreme 1.44
85.3
10 years 1.44
Extreme 1.44
93
Manager TitleAgeSince
Chief Executive Officer 54 31/12/2018
President 49 31/12/2016
Director of Finance/CFO 51 02/05/2021
Director TitleAgeSince
Director/Board Member 54 -
Director/Board Member 57 -
Chairman 45 22/04/2025
Date Insider Type Main position Quantity % Market Cap.
26/03/25BuyCompany 3,000,000 0.9187%
19/12/24Sell

Director

100,000 0.0306%
19/12/24Buy

Director

100,000 0.0306%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-8.39%+58.24%-89.80% 94.87M
-1.39%-7.58%+54.00%+124.73% 54.49B
+3.13%+11.16%+67.30%+94.35% 55.93B
-0.27%-2.69%+7.77%+433.06% 23.87B
+1.76%-2.44%-17.13%-15.01% 22.86B
+3.51%+7.50%+47.81%-3.33% 20B
+1.94%-0.03%+38.19%-27.77% 17.48B
+10.00%-2.06%+210.10%+370.99% 15.39B
+7.69%+4.38%+56.51%+712.88% 15.19B
-0.39%-2.68%+21.87%+186.49% 14.02B
Average +2.60%-0.45%+54.47%+178.66% 23.93B
Weighted average by Cap. +2.10%+0.47%+52.35%+169.90%

Financials

2026 *2027 *
Net sales - 162M 16.72M 14.62M 13.49M 12.4M 23.49M 1.61B 23.89M 161M 63.17M 786M 62.79M 61.41M 2.71B
Net income -208M -21.5M -18.8M -17.34M -15.94M -30.2M -2.07B -30.72M -207M -81.22M -1.01B -80.73M -78.96M -3.48B -41.58M -4.3M -3.76M -3.47M -3.19M -6.04M -414M -6.14M -41.4M -16.24M -202M -16.15M -15.79M -697M
Net Debt -485M -50.16M -43.86M -40.46M -37.19M -70.46M -4.83B -71.67M -483M -190M -2.36B -188M -184M -8.13B -578M -59.71M -52.21M -48.16M -44.27M -83.89M -5.75B -85.32M -575M -226M -2.81B -224M -219M -9.68B
Logo Nykode Therapeutics
Nykode Therapeutics ASA is a Norway-based clinical-stage biopharmaceutical platform company dedicated to the discovery and development of vaccines and immunotherapies for cancer and infectious diseases. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The Company develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The Company also has two universal COVID-19 vaccine candidates in development.
Employees
57
Date Price Change Volume
15/07/26 NOK 2.785 -0.89% 389,304
14/07/26 NOK 2.810 +1.44% 313,393
13/07/26 NOK 2.770 -3.15% 381,366
10/07/26 NOK 2.860 -0.69% 271,960
09/07/26 NOK 2.880 -3.68% 396,126
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.785NOK
Average target price
5.000NOK
Spread / Average Target
+79.53%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VACC Stock